JP6154566B1 - Chinese medicine to normalize hormonal abnormalities of hypothyroidism due to chronic thyroiditis - Google Patents

Chinese medicine to normalize hormonal abnormalities of hypothyroidism due to chronic thyroiditis Download PDF

Info

Publication number
JP6154566B1
JP6154566B1 JP2017081441A JP2017081441A JP6154566B1 JP 6154566 B1 JP6154566 B1 JP 6154566B1 JP 2017081441 A JP2017081441 A JP 2017081441A JP 2017081441 A JP2017081441 A JP 2017081441A JP 6154566 B1 JP6154566 B1 JP 6154566B1
Authority
JP
Japan
Prior art keywords
hypothyroidism
chronic thyroiditis
chinese medicine
extract
hormonal abnormalities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017081441A
Other languages
Japanese (ja)
Other versions
JP2018177720A (en
Inventor
義輝 霜出
義輝 霜出
Original Assignee
義輝 霜出
義輝 霜出
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 義輝 霜出, 義輝 霜出 filed Critical 義輝 霜出
Priority to JP2017081441A priority Critical patent/JP6154566B1/en
Application granted granted Critical
Publication of JP6154566B1 publication Critical patent/JP6154566B1/en
Publication of JP2018177720A publication Critical patent/JP2018177720A/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

【課題】慢性甲状腺炎による甲状腺機能低下症のホルモン異常を正常化させる組成物の提供。【解決手段】黄連解毒湯及び苓桂朮甘湯の合剤を有効成分として含む慢性甲状腺炎による甲状腺機能低下症のホルモン異常を正常化させる漢方薬。【選択図】なしThe present invention provides a composition for normalizing hormonal abnormalities in hypothyroidism caused by chronic thyroiditis. [Solution] A Chinese medicine that normalizes hormonal abnormalities of hypothyroidism caused by chronic thyroiditis, which contains a combination of Houren Deto-to and Kankei-kanto. [Selection figure] None

Description

本発明は漢方薬の合剤を含む慢性甲状腺炎による甲状腺機能低下症のホルモン異常を正常化させる組成物に関する。   The present invention relates to a composition for normalizing hormonal abnormalities in hypothyroidism caused by chronic thyroiditis, which contains a combination of traditional Chinese medicines.

漢方薬は複数の生薬を組合せた方剤をいい、患者の体全体の調子を整えることで疾患を治療する。漢方薬は患者の症状(東洋医学における証(Sho))に基づいて生薬が選択され投与される。   Chinese herbal medicine is a combination of herbal medicines that treats the disease by adjusting the condition of the patient's entire body. Herbal medicine is selected and administered based on the patient's symptoms (Sho in Oriental medicine).

慢性甲状腺炎における甲状腺機能低下症は、原発性甲状腺機能低下症の殆ど大部分を占めている疾患である。慢性甲状腺炎の原因は、1956年イギリスのRoitt, Doniachらが本症患者血中に抗サイログロブリン抗体を発見し、同年アメリカのWhitebsky, Roseが実験的に甲状腺炎を作成することに成功し、甲状腺における慢性的な炎症は自己免疫が関与している炎症であることが判明した。つまり、慢性甲状腺炎による甲状腺機能低下症のホルモン異常は自己免疫機序による甲状腺組織の障害であることが示された。   Hypothyroidism in chronic thyroiditis is a disease that accounts for the majority of primary hypothyroidism. In 1956, Roitt, Doniach et al. Of the UK discovered an anti-thyroglobulin antibody in the blood of a patient with this disease, and in the same year, Whitebsky, Rose of the United States succeeded in experimentally creating thyroiditis. Chronic inflammation in was found to be inflammation involving autoimmunity. In other words, it was shown that the hormonal abnormality of hypothyroidism caused by chronic thyroiditis is a disorder of thyroid tissue due to an autoimmune mechanism.

血中甲状腺ホルモンと下垂体TSH分泌との間には負のフィードバックがあるため、甲状腺性甲状腺機能低下症では血中TSHが増加する。そのため慢性甲状腺炎における甲状腺機能低下症には、FT4(free thyroxine)は正常値でTSH(thyroid stimulating hormone)だけが上昇する潜在性甲状腺機能低下症とTSH(thyroid stimulating hormone)上昇に加えFT4(free thyroxine)の低下を示す顕性甲状腺機能低下症がある。通常、顕性甲状腺機能低下症では、甲状腺ホルモン補充療法を速やかに開始する。しかし潜在性甲状腺機能低下症の場合はTSH(thyroid stimulating hormone)が概ね10ng/dl以上に上昇してきたときに甲状腺ホルモン補充療法を開始することが臨床的には通常である。つまり、慢性甲状腺炎における甲状腺機能低下症のFT4の正常値又は低値にかかわらず、TSHの上昇を示すホルモン異常に対する治療法は、ホルモン補充療法しか存在していない。ホルモン補充療法は、慢性甲状腺炎に対する根本的な治療法ではなく、原因を改善することはないため殆どの症例において一生涯治療を続けなければならないことがホルモン補充療法の欠点である。また、現在までにおいて慢性甲状腺炎による潜在性甲状腺機能低下症、及び顕性甲状腺機能低下症における甲状腺ホルモン異常を治療することができる薬剤は、乾燥甲状腺、合成T3と合成T4製剤の3種の甲状腺ホルモンだけである。これらの甲状腺ホルモンは、併用に注意を要する薬剤が多種あり、また甲状腺ホルモンに起因する副作用が多数存在し、副作用が出現した場合、他に慢性甲状腺炎による甲状腺機能低下症のホルモン異常を正常化させる治療法が存在していない。   Because there is negative feedback between blood thyroid hormone and pituitary TSH secretion, blood TSH increases in hypothyroidism. Therefore, for hypothyroidism in chronic thyroiditis, FT4 (free thyroxine) is normal and only TSH (thyroid stimulating hormone) rises. In addition to latent hypothyroidism and TSH (thyroid stimulating hormone) rise, FT4 (free There is overt hypothyroidism that shows a decrease in thyroxine. Usually, for overt hypothyroidism, thyroid hormone replacement therapy is started immediately. However, in the case of latent hypothyroidism, it is clinically usual to start thyroid hormone replacement therapy when TSH (thyroid stimulating hormone) rises to approximately 10 ng / dl or more. In other words, regardless of the normal or low value of FT4 for hypothyroidism in chronic thyroiditis, only hormone replacement therapy exists for the treatment of hormone abnormalities that show an increase in TSH. Hormone replacement therapy is not a fundamental cure for chronic thyroiditis and does not improve the cause, so it is a disadvantage of hormone replacement therapy that it must be treated for the lifetime in most cases. To date, there are three types of thyroid gland, dry thyroid, synthetic T3 and synthetic T4 preparations, which can treat latent hypothyroidism due to chronic thyroiditis and thyroid hormone abnormalities in overt hypothyroidism. Only hormones. These thyroid hormones have a variety of drugs that require attention in combination, and there are many side effects caused by thyroid hormones, and when side effects appear, normalize hormonal abnormalities of hypothyroidism caused by chronic thyroiditis. There is no cure to make it happen.

加えて、漢方薬を使っての治療法は、甲状腺機能低下症の新陳代謝の低下、冷えの症状などに対する効果に基づいて経験的に真武湯、人参湯、補中益気湯、当帰芍薬散、温経湯、五苓散、桂枝加芍薬湯、桂枝加芍薬大黄湯、小建中湯、柴胡桂枝乾姜湯、附子などが用いられることはあるが、慢性甲状腺炎による甲状腺機能低下症のホルモン異常を正常化させることができる治療薬ではない。また、原因が特定されていない3例の高齢者の甲状腺機能低下症に対し補中益気湯が有用であった報告(非特許文献1参照)、さらに、動物実験ではあるが、ラットに人為的に投与された甲状腺ホルモン合成阻害剤Metimazoleによる甲状腺機能低下症からの回復に抑肝散加陳皮半夏と温経湯が有効であることが報告された(非特許文献2参照)が、その動物実験モデルでの甲状腺機能低下は、甲状腺ホルモン合成阻害剤Metimazoleからの甲状腺ホルモンの回復の検討であり、慢性甲状腺炎とは病因が異なるため、臨床的にも全く抑肝散加陳皮半夏と温経湯の漢方薬は使われていない。つまり、慢性甲状腺炎による甲状腺機能低下症のホルモン異常を正常化させる治療薬は、漢方薬治療において存在していないため、慢性甲状腺炎による甲状腺機能低下症のホルモン異常の治療は、ホルモン補充療法しか行われていない。   In addition, treatment with Kampo medicines has been empirically based on the effects on hypometabolism, decreased metabolism, cold symptoms, etc.Shinbuto, Ninjinto, Hochuekkito, Tokiyakuyakusan, Onkei-to, Gojosan, Keishika-ka-yaku-yu, Keishi-ka-ka-yaku-daiko-to, Koken-chu-yu, Saiko-Kei-sha-sui-to, and tsutsuji are sometimes used, but hypothyroidism due to chronic thyroiditis It is not a treatment that can normalize hormonal abnormalities. In addition, Hochuekkito was useful for hypothyroidism in 3 elderly patients whose cause was not specified (see Non-Patent Document 1). It has been reported that Yokukansanka-Chan-Summer and Unkei-to are effective in recovering from hypothyroidism with the thyroid hormone synthesis inhibitor Metimazole administered locally (see Non-Patent Document 2). Hypothyroidism in animal experimental models is an examination of the recovery of thyroid hormone from the thyroid hormone synthesis inhibitor Metimazole, and since its etiology is different from chronic thyroiditis, it is clinically completely Unkeito herbal medicine is not used. In other words, since there is no treatment for normalizing hormonal abnormalities in hypothyroidism due to chronic thyroiditis in Chinese medicine treatment, only hormone replacement therapy can be used to treat hormonal abnormalities in hypothyroidism due to chronic thyroiditis. I have not been told.

山口愛二:神奈川県医師会報:44-47,1991Ai Yamaguchi: Kanagawa Medical Association Bulletin: 44-47,1991 須川秀夫、他:ホルモンと臨床43(6):637-642,1995Hideo Sugawa, et al .: Hormone and Clinical 43 (6): 637-642,1995

本発明は黄連解毒湯(オウレンゲドクトウ)及び苓桂朮甘湯(リョウケイジュツカントウ)の合剤を有効成分として含む慢性甲状腺炎による甲状腺機能低下症のホルモン異常を正常化させる組成物の提供を目的とする。   The present invention provides a composition for normalizing hormonal abnormalities in hypothyroidism caused by chronic thyroiditis, which contains a combination of Orendetoto and Ryoketsukanto as active ingredients. With the goal.

現在までの漢方薬治療では全く慢性甲状腺炎による甲状腺機能低下症のホルモン異常を治療できるものは存在していないが、本発明者は慢性甲状腺炎による甲状腺機能低下症のホルモン異常を正常化させることができる漢方薬を開発できた。つまり、黄連解毒湯と苓桂朮甘湯の混合漢方薬は慢性甲状腺炎による甲状腺機能低下症のホルモン異常を示す患者の91.20%を正常化させることができ、本発明を完成させるに至った。   Until now, there is no medicine that can treat hormonal abnormality of hypothyroidism caused by chronic thyroiditis, but the present inventor can normalize hormonal abnormality of hypothyroidism caused by chronic thyroiditis. We were able to develop a Chinese medicine that can be used. In other words, the mixed Chinese medicine of Houren Deto-to and Sakai Keitou-to can normalize 91.20% of patients with hormonal abnormalities of hypothyroidism due to chronic thyroiditis, thus completing the present invention.

すなわち、本発明は以下のとおりである。
[1] 黄連解毒湯及び苓桂朮甘湯の合剤を有効成分として含む慢性甲状腺炎による甲状腺機能低下症のホルモン異常を正常化させる漢方薬。
That is, the present invention is as follows.
[1] A traditional Chinese medicine that normalizes hormonal abnormalities in hypothyroidism caused by chronic thyroiditis, which contains a combination of Hou Ren Deto and Tokei Katsura Ayu.

本発明の黄連解毒湯及び苓桂朮甘湯の合剤を有効成分として含む組成物は、慢性甲状腺炎による甲状腺機能低下症のホルモン異常を正常化させることができる。   The composition containing the combination of Huangren detoxification and keikeienkanto as an active ingredient of the present invention can normalize hormonal abnormalities of hypothyroidism caused by chronic thyroiditis.

以下、本発明を詳細に説明する。
本発明の組成物は、黄連解毒湯(オウレンゲドクトウ:Formula antidoti coptidis)及び苓桂朮甘湯(リョウケイジュツカントウ:Formula glycyrrhizae atractylodis cinnamomi hoelen)を有効成分として含む、黄連解毒湯及び苓桂朮甘湯の合剤である。
Hereinafter, the present invention will be described in detail.
The composition of the present invention comprises Huangren Detoyu and Otsukushien, which contain, as active ingredients, Huangrendetoto (Formula antidoti coptidis) and Formula glycyrrhizae atractylodis cinnamomi hoelen. It is a mixture of Amayu.

黄連解毒湯(オウレンゲドクトウ)は、生薬である黄連(オウレン)(Copridis Rhizoma)、黄ごん(オウゴン)(Scutellariae Radix)、黄柏(オウバク)(Phellodendri Cortex)及び山梔子(サンシシ)(Gardeniae Fructus)を配合した漢方薬である。成人における1日量は、それぞれの乾燥生薬の配合重量は、例えば黄連1.5g〜2.0g、黄ごん3.0g、黄柏1.5g〜3.0g、山梔子2.0g〜3.0gである。   Orendetoto is a herbal medicine, Copridis Rhizoma, Scutellariae Radix, Phellodendri Cortex, and Gardeniae Fructus). As for the daily dose in adults, the blended weight of each dry crude drug is, for example, 1.5 g to 2.0 g of yellow chain, 3.0 g of yellow rice, 1.5 g to 3.0 g of jaundice, and 2.0 g to 3.0 g of yam.

以下、黄連、黄ごん、黄柏及び山梔子について説明するが、以下に示したもの以外のものを指すこともある。黄連は、キンポウゲ科(Ranunculaceae)のオウレンCoptis japonica Makino又は他の同属植物の根をほとんど除いた根茎を乾燥したものをいう。黄ごんはシソ科(Labiatae)のコガネバナScutellaria baicalensis Georgiの周皮を除いた根を乾燥したものをいう。黄柏はミカン科(Rutaceae)キハダPhellodendron amurense RUPR.又はその他同属植物の周皮(コルク皮)を除いた樹皮を乾燥したものをいう。その他同属植物として例えばシナキハダPhellodendron chinense Schneiderが挙げられる。山梔子はアカネ科(Rubiaceae)のクチナシGardenia jasminoides ellis又はその他同属植物の果実を乾燥したものをいう。   In the following, yellow chain, yellow rice, jaundice and yam will be described, but things other than those shown below may be indicated. Yellow ream refers to a dried rhizome except for the roots of Ranunculaceae's Crenis Coptis japonica Makino or other related plants. Yellow gourd means dried roots excluding the pericarp of Scutellaria baicalensis Georgi from Labiatae. Jaundice refers to dried bark excluding the pericarp (cork skin) of the Rutaceae yellowfin Phellodendron amurense RUPR. Or other related genera. Other plants belonging to the same genus include, for example, the cinnamon hinder Phellodendron chinense Schneider. Mountain lion refers to the dried fruits of Gardenia jasminoides ellis or other related plants of the Rubiaceae family.

黄連解毒湯は上記の4種類の生薬のエキス製剤を入手して上記配合重量で混合することにより製造することができる。若しくは、上記4種類の乾燥生薬を上記配合重量で600mlの湯に入れ1時間かけて300mlにまで煮出(濃縮)し、その300mlを1日量として製造することができる。それぞれの漢方薬1回100mlを混合し1回200mlとし毎食前に1日3回服用するようにする。それぞれの漢方薬1回150mlを混合し1回300mlとし朝夕食前に1日2回服用するようにすることもできる。   Korentoto can be produced by obtaining the above four kinds of herbal extract preparations and mixing them at the above blending weight. Alternatively, the above four kinds of dry herbal medicines can be produced in 600 ml of hot water at the above blending weight and boiled (concentrated) to 300 ml over 1 hour, and 300 ml can be produced as a daily dose. Mix 100 ml of each herbal medicine once to make 200 ml once and take 3 times a day before each meal. You can mix 150ml of each herbal medicine once to make 300ml once and take it twice a day before breakfast and dinner.

また、市販のものを用いることもできる。市販のものとして、オースギ黄連解毒湯エキスT錠(大杉製薬)、クラシエ黄連解毒湯エキス錠(クラシエ薬品)、コタロー黄連解毒湯エキス細粒(小太郎漢方製薬)、サカモト黄連解毒湯エキス顆粒-S(阪本漢法製薬)、ツムラ黄連解毒湯エキス顆粒(医療用)(ツムラ)、JPS黄連解毒湯エキス顆粒(調剤用)(ジェーピーエス)等がある。   Commercially available products can also be used. As a commercially available product, Osugi Hokuren Detox Extract T Tablet (Osugi Pharmaceutical), Kracie Hokuren Detox Extract (Krasie Yakuhin), Kotaro Hokuren Detox Extract Fine Granules (Kotaro Kampo Pharmaceutical), Sakamoto Hokuren Detox Extract Granule-S (Sakamoto Hanpo Pharmaceutical Co., Ltd.), Tsumura Korentoto extract granule (for medical use) (Tsumura), JPS Korentoto extract granule (for dispensing) (JP).

苓桂朮甘湯(リョウケイジュツカントウ)は、茯苓(ブクリョウ)(Hoelen)、蒼朮(ソウジュツ)(Atractylodis Lanceae Rhizoma)若しくは白朮(ビャクジュツ)(Atractylodis Rhizoma)、桂皮(ケイヒ)(Cinnamomi Cortex)並びに甘草(カンゾウ)(Glycyrrhizae Radix)を配合した生薬である。成人における1日量は、それぞれの乾燥生薬の配合重量比は、例えば、茯苓4g〜6g、蒼朮若しくは白朮2g〜3g、桂皮3g〜4g、甘草1g〜2gである。   Ryokei tsukanto can be found in Hoelen, Atractylodis Lanceae Rhizoma, Atractylodis Rhizoma, Cinnamomi Cortex and licorice ( It is a herbal medicine containing Glycyrrhizae Radix. As for the daily dose in adults, the blended weight ratio of each dry crude drug is, for example, cocoon 4 g to 6 g, cocoon or white cocoon 2 g to 3 g, cinnamon 3 g to 4 g, and licorice 1 g to 2 g.

以下、茯苓及び桂皮について説明するが、以下に示したもの以外のものを指すこともある。蒼朮若しくは白朮並びに甘草は上記のとおりである。   Hereinafter, cocoons and cinnamon will be described, but things other than those shown below may be indicated. Salmon or birch and licorice are as described above.

茯苓は、サルノコシカケ科(Polyporaceae)のマツホドPoria cocos Wolfの菌核をそのまま、又は外層をほとんど除いて乾燥したものをいう。桂皮はクスノキ科(Lauraceae)のCinnamomum cassia Blume又はその他同属植物の樹皮を乾燥したものをいう。   Acupuncture refers to a dried potato nucleus of the Porphya cocos Wolf from the Polyporaceae family as it is or with almost no outer layer removed. Cinnamon means dried bark of Cinnamomum cassia Blume of Lauraceae or other related genera.

苓桂朮甘湯は上記の4種類の生薬のエキス製剤を入手して上記配合量で混合することにより製造することができる。若しくは、上記4種類の乾燥生薬を上記配合量で600mlの湯に入れ1時間かけて300mlにまで煮出し、その300mlを1日量として製造することができる。また、市販のものを用いることもできる。市販のものとして、クラシエ苓桂朮甘湯エキス細粒(クラシエ薬品)、コタロー苓桂朮甘湯エキス細粒(小太郎漢方製薬)、ツムラ苓桂朮甘湯エキス顆粒(ツムラ)、オースギ苓桂朮甘湯エキスTG(大杉製薬)、JPS苓桂朮甘湯エキス顆粒(調剤用)(ジェーピーエス)等がある。   苓 桂 朮 甘 湯 can be produced by obtaining the above four kinds of herbal extracts and mixing them in the above amounts. Alternatively, the above four kinds of dry crude drugs can be produced in the above blending amount in 600 ml of hot water and boiled to 300 ml over 1 hour, and 300 ml can be produced as a daily dose. Commercially available products can also be used. As a commercially available product, Kracie 苓 Katsura Ayu Extract Fine Granule (Krasie Yakuhin), Kotaro 苓 Katsura Ayu Extract Fine Granule (Kotaro Kampo Pharmaceutical), Tsumura 苓 Katsura Ayu Extract Granule (Tsumura), Osugi 苓 Katsura Ayu Extract TG (Osugi Pharmaceutical Co., Ltd.), JPS 苓 Katsura Ayu Extract Granule (for dispensing) (JP S) and the like.

黄連解毒湯又は苓桂朮甘湯に含まれる生薬のエキスは、例えば上記生薬を水若しくは熱水、エタノール、酢酸等でエキスを抽出し、スプレードライや凍結乾燥により乾燥し粉末として用いることができる。該粉末を混合し、黄連解毒湯又は苓桂朮甘湯を製造し、これらを混合し合剤を製造する。   The herbal medicine extract contained in Hou Ren Detoyu or Sakai Katsura Ayuto can be used as a powder, for example, by extracting the above herbal medicine with water or hot water, ethanol, acetic acid, etc., and drying by spray drying or freeze drying. . The powder is mixed to produce Huangren Detoxification Hot Water or Sakai Keikanto, and these are mixed to produce a mixture.

黄連解毒湯及び苓桂朮甘湯の合剤は成人1日用量として黄連解毒湯乾燥エキス末1.3g〜2.71gと苓桂朮甘湯乾燥エキス末1.5g〜7gを混合すればよい。この場合、それぞれの漢方薬1回100mlを混合し1回200mlとし毎食前に1日3回服用するようにする。それぞれの漢方薬1回150mlを混合し1回300mlとし朝夕食前に1日2回服用するようにすることもできる。市販漢方薬エキスを用いる場合、市販黄連解毒湯エキス及び市販苓桂朮甘湯の指定された1日量をそれぞれ3分割し、混合して1日3回食前に服用するようにすればよい。また、市販黄連解毒湯エキス及び市販苓桂朮甘湯の指定された1日量をそれぞれ2分割し、混合して1日2回朝夕食前に服用させるようにしてもよい。混合したものを通常の製剤に用いる適当な賦形剤、補助剤等を加えて製剤製造の常法に従って散剤、顆粒剤、錠剤、カプセル剤、液剤、シロップ剤等の経口製剤とすることにより本発明の組成物を得ることができる。また、その他適宜結合剤、崩壊剤、界面活性剤、矯味剤、香料を配合してもよい。賦形剤として例えば、デンプン、デキストリン、乳糖、白糖、マンニット、結晶セルロース、無水ケイ酸等が挙げられる。   As a daily dose for adults, the combination of Huangren Detoyu and Tokei Katsuri-Ayu may be mixed with 1.3 g to 2.71 g of Huangren Detox Dry Extract Powder and 1.5 g to 7 g of Totsuo Kaito Sweet Dry Powder. In this case, mix 100 ml of each Chinese medicine once to make 200 ml once and take 3 times a day before each meal. You can mix 150ml of each herbal medicine once to make 300ml once and take it twice a day before breakfast and dinner. When using a commercially available Chinese herbal medicine extract, the designated daily doses of the commercial yellow renzento extract and the commercially available katsura candy sweet water may be divided into three, mixed and taken three times a day before meals. In addition, the designated daily doses of the commercially available Huangren Detox extract and the commercially available katsura candy sweet water may be divided into two, mixed and taken twice a day before dinner in the morning. Add the appropriate excipients, adjuvants, etc. used in normal preparations and mix them into oral preparations such as powders, granules, tablets, capsules, liquids, syrups, etc. according to conventional methods for preparation. Inventive compositions can be obtained. Moreover, you may mix | blend binder, a disintegrating agent, surfactant, a corrigent, and a fragrance | flavor suitably. Examples of the excipient include starch, dextrin, lactose, sucrose, mannitol, crystalline cellulose, and silicic anhydride.

本発明の組成物は、その剤型に応じて異なるが、通常全組成物中黄連解毒湯及び苓桂朮甘湯が0.1〜100重量%程度含まれる。本発明の組成物の患者への投与量は患者の年齢を考慮して、1日1回又は数回に分けて、数日から数十カ月にわたって投与すればよい。   The composition of the present invention varies depending on the dosage form, but usually contains about 0.1 to 100% by weight of Hou Ren Deto-to and Tokei Katsuri-anto in the entire composition. The dose of the composition of the present invention to a patient may be administered over several days to several tens of months, taking into account the age of the patient, once a day or divided into several times.

本発明の黄連解毒湯及び苓桂朮甘湯の合剤は、慢性甲状腺炎による甲状腺機能低下症のホルモン異常を正常化させる。   The combination of Huangren detoxification and keikeienkanto normalizes the hormonal abnormality of hypothyroidism caused by chronic thyroiditis.

黄連解毒湯及び苓桂朮甘湯の合剤は慢性甲状腺炎による甲状腺機能低下症のホルモン異常の治療薬として用いることができる。また、黄連解毒湯及び苓桂朮甘湯の合剤は慢性甲状腺炎による甲状腺機能低下症の治療薬として用いることができる。   The combination of Hou Ren Deto-to and Sakai Keito-to can be used as a treatment for hormonal abnormalities in hypothyroidism caused by chronic thyroiditis. In addition, a combination of Houren Deto-to and Sakaikeitokanto can be used as a therapeutic agent for hypothyroidism caused by chronic thyroiditis.

投与量は、例えば成人における場合、市販医療用漢方エキス製剤で1日用量が7.5gあれば、各々の漢方薬2.5gずつの混合合剤を食前に1日3回経口投与する。各々の患者の反応により異なるが、患者の症状及び皮膚炎症が消失するまで投与する。また、患者が17歳未満の非成人の場合、表1に示す年齢別薬用量に従って、投与すればよい。   For example, in the case of an adult, if the daily medical dose is 7.5 g for a commercial medical Kampo extract, 2.5 g of each Kampo medicine is orally administered three times a day before meals. Depending on the response of each patient, it is administered until the patient's symptoms and skin inflammation disappear. Moreover, what is necessary is just to administer according to the dosage according to age shown in Table 1 when a patient is a non-adult under 17 years old.

Figure 0006154566
Figure 0006154566

例えば成人における場合、市販医療用漢方エキス製剤で1日用量が7.5gであれば、黄連解毒湯2.5gと苓桂朮甘湯2.5gの混合合剤を食前に1日3回経口投与する。症状消失までの期間投与する。   For example, in the case of an adult, if the daily dosage is 7.5 g for a commercially available medical herbal extract preparation, a mixed mixture of 2.5 g of Hou Ren Deto-to and 2.5 g of Tokeikei-kanto is orally administered three times a day before meals. Administer for the period until symptoms disappear.

本発明の組成物は、ヒトを含む哺乳動物を対象とすることができる。ヒト以外の哺乳動物としては、例えば、サルなどの霊長類、ラット、マウスなどのげっ歯類、ヒツジ、ブタ、ウシ、ネコ、イヌ等が挙げられる。   The composition of the present invention can be used for mammals including humans. Examples of mammals other than humans include primates such as monkeys, rodents such as rats and mice, sheep, pigs, cows, cats and dogs.

さらに、本発明の組成物を食品、飲料品に混合し飲食品組成物又は飼料組成物として使用することができる。この際、飲食品又は飼料の1回の摂取分量に対して黄連解毒湯及び苓桂朮甘湯を例えば市販医療用漢方薬エキスが人において1日量が7.5gの場合、100mg/kgの量となるように配合すればよい。本発明の組成物は、粉末、顆粒状、液状、ペースト状などの飲食品組成物又は飼料組成物として用いることもできる。飲食品は、機能性表示食品、健康飲食品、特定保健用飲食品、栄養機能飲食品、健康補助飲食品等を含む。ここで、特定保健用食品とは、食生活において特定の保健の目的で摂取をし、その摂取により当該保健の目的が期待できる旨の表示をする食品をいう。また、機能性表示食品とは、事業者の責任で、化学的根拠を基に商品パッケージに機能性を表示する食品をいう。   Furthermore, the composition of this invention can be mixed with a foodstuff and a drink, and can be used as a food-drinks composition or a feed composition. At this time, for example, when the daily dose of a commercially available Chinese herbal medicine extract is 7.5 g in humans, the amount of 100 mg / kg What is necessary is just to mix | blend. The composition of the present invention can also be used as a food / beverage composition or feed composition such as powder, granule, liquid or paste. The foods and drinks include functional display foods, health foods and drinks, specific health foods and drinks, nutritional functional foods and drinks, health supplement foods and drinks, and the like. Here, the food for specified health refers to food that is ingested for the purpose of specific health in the diet and displays that the purpose of the health can be expected by the intake. The functional labeling food means food that displays the functionality on the product package based on the chemical basis at the responsibility of the operator.

本発明を以下の実施例によって具体的に説明するが、本発明はこれらの実施例によって限定されるものではない。   The present invention will be specifically described by the following examples, but the present invention is not limited to these examples.

実施例1 黄連解毒湯及び苓桂朮甘湯の合剤の調製
実施例においては、市販漢方薬エキスを用い、市販黄連解毒湯エキス及び市販苓桂朮甘湯の指定された1日量をそれぞれ3分割し、混合して1日3回食前に服用するようにした。市販黄連解毒湯エキス及び市販苓桂朮甘湯の指定された1日量をそれぞれ2分割し、混合して1日2回朝夕食前に服用することもできる。
Example 1 Preparation of a combination of Hou Ren Deto-to and Sakai Katsura Ayu In the examples, a commercially available Chinese herbal medicine extract was used, and the specified daily doses of 3 Divide, mix and take 3 times a day before meals. The designated daily doses of commercially available Huangren detox extract and commercially available katsura candy sweet water can be divided into two, mixed and taken twice a day before dinner in the morning.

実施例2 慢性甲状腺炎による甲状腺機能低下症のホルモン異常の正常化
対象は、原発性甲状腺機能低下症の症例で日本甲状腺学会甲状腺機能低下症ガイドライン2010、及び日本甲状腺学会慢性甲状腺炎ガイドライン2010に基づいて臨床的に診断された慢性甲状腺炎による潜在性甲状腺機能低下症、及び顕性甲状腺機能低下症患者57例(男性:女性=9:48、平均年齢42.8±13.8才(mean±SD)(29才〜98才))であった。対象とした症例において、潜在性甲状腺機能低下症患者は、41例であり、慢性甲状腺炎による顕性甲状腺機能低下症患者は16例であった。観察期間は、2007年12月より2017年1月の約9年間であった。黄連解毒湯と苓桂朮甘湯の混合漢方薬治療群は34例であり、Control群は23例であった。Control群においては23例中16例が潜在性甲状腺機能低下症であり、7例が顕性甲状腺機能低下症であった。黄連解毒湯と苓桂朮甘湯の混合漢方薬治療群34例中22例が慢性甲状腺炎による潜在性甲状腺機能低下症患者であり、12例が慢性甲状腺炎による顕性甲状腺機能低下症であった。慢性甲状腺炎による顕性甲状腺機能低下症の16例中15例は、種々の量の甲状腺ホルモンであるlevothyroxine sodium hydrate(T4-Na)の投与を受けていた。正常値は、TSH(thyroid stimulating hormone《thyrotropin》)は、RIA固相法で0.35〜3.73μIU/mL、FT4(free thyroxine)は、ECLIAで0.9〜1.8ng/dlを用いた。統計処理は、Student's T test、Chi square testを用いた。
Example 2 Normalization of Hormone Abnormalities of Hypothyroidism due to Chronic Thyroiditis Subject is a case of primary hypothyroidism based on the Japanese Thyroid Society Hypothyroidism Guideline 2010 and the Japanese Thyroid Society Chronic Thyroiditis Guideline 2010 57 patients with latent hypothyroidism due to chronic thyroiditis diagnosed clinically and overt hypothyroidism (male: female = 9:48, mean age 42.8 ± 13.8 years (mean ± SD) (29 Years old to 98 years old)). In the targeted cases, there were 41 patients with latent hypothyroidism and 16 patients with overt hypothyroidism due to chronic thyroiditis. The observation period was about nine years from December 2007 to January 2017. There were 34 mixed Chinese herbal medicine treatment groups of Hou Ren Deto and Tokei Katsuri Ayu, and 23 in the Control group. In the Control group, 16 of 23 cases had latent hypothyroidism and 7 cases had overt hypothyroidism. Of 34 patients treated with Huangren detoxin and keikei kankanto, 22 patients had latent hypothyroidism due to chronic thyroiditis, and 12 patients had overt hypothyroidism due to chronic thyroiditis. . Fifteen of 16 cases of overt hypothyroidism due to chronic thyroiditis received various doses of levothyroxine sodium hydrate (T4-Na). Normal values of TSH (thyroid stimulating hormone << thyrotropin >>) were 0.35 to 3.73 μIU / mL by RIA solid phase method, and 0.9 to 1.8 ng / dl of ECLIA was used for FT4 (free thyroxine). Statistical processing used Student's T test and Chi square test.

結果:
Control群13.0%(3/23)において観察中に慢性甲状腺炎による甲状腺機能低下症におけるホルモン異常の指標の一つであるTSHが正常値になった。黄連解毒湯と苓桂朮甘湯の混合漢方薬投与群においては、治療により91.2%(31/34)の症例においてTSHが正常値になった。カイ二乗検定において黄連解毒湯と苓桂朮甘湯の混合漢方薬が有意(p<0.001)に慢性甲状腺炎による甲状腺機能低下症のTSHを正常化させることができた。また、control群において観察開始時TSH3.37±1.48(mean±SD)(n=23)、観察終了時5.26±2.26(mean±SD)(n=23)であり有意(P<0.001)にホルモン異常が悪化したが、黄連解毒湯と苓桂朮甘湯の混合漢方薬投与群においては、投与前TSH7.62±2.60(mean±SD)(n=34)、投与後2.97±0.26(mean±SD)(n=34)で有意(p<0.05)にTSHが低下し正常化した。FT4は前後において両群ともに有意な変動はなかったが黄連解毒湯と苓桂朮甘湯の混合漢方薬治療群において投与前にFT4低下例3例中3例がFT4も正常化した。つまり、黄連解毒湯と苓桂朮甘湯の混合漢方薬は慢性甲状腺炎による甲状腺機能低下症のホルモン異常を有意に正常化できる新規の漢方薬である。
result:
In the 13.0% (3/23) group in the control group, TSH, which is one of the indicators of hormone abnormalities in hypothyroidism due to chronic thyroiditis, became normal. In the group treated with the mixed Chinese herbal medicine of Hou Ren Deto and Tokei Katsuri Ato, the TSH level was normal in 91.2% (31/34) of the cases. In the chi-square test, the mixed Chinese medicine of Houren Deto-to and Sakaikeikanto was able to significantly normalize TSH of hypothyroidism due to chronic thyroiditis (p <0.001). In the control group, TSH3.37 ± 1.48 (mean ± SD) (n = 23) at the start of observation, 5.26 ± 2.26 (mean ± SD) (n = 23) at the end of observation, and significant (P <0.001) hormone Abnormalities worsened, but in the Chinese herbal medicine administration group of Huangren Detox and Tokeikei-kanto, TSH7.62 ± 2.60 (mean ± SD) (n = 34) before administration, 2.97 ± 0.26 (mean ± SD) after administration ) (N = 34), TSH decreased significantly and normalized (p <0.05). There was no significant change in FT4 in both groups before and after, but in the mixed Chinese herbal medicine treatment group of Hokuren detoxin and 苓 Katsurakanto, 3 out of 3 cases with FT4 declined before administration, FT4 also normalized. In other words, the mixed Chinese herbal medicine of Houren Deto-to and Sakaikeikanto is a novel Chinese medicine that can significantly normalize the hormonal abnormality of hypothyroidism caused by chronic thyroiditis.

結論:
ホルモン補充療法以外では人間に投与して慢性甲状腺炎による甲状腺機能低下症のホルモン異常を治療できる唯一の薬剤である黄連解毒湯と苓桂朮甘湯の混合漢方薬を開発できた。
Conclusion:
Other than hormone replacement therapy, we were able to develop a mixed Chinese medicine of Houren Deto-to and Sugakei-anto which is the only drug that can be administered to humans to treat hormonal abnormalities of hypothyroidism caused by chronic thyroiditis.

本発明の黄連解毒湯及び苓桂朮甘湯の合剤を有効成分として含む組成物は慢性甲状腺炎による甲状腺機能低下症のホルモン異常を正常化に利用することができる。   The composition containing the combination of Huangren detoxification and keikeienkanto as an active ingredient of the present invention can be used to normalize hormonal abnormalities of hypothyroidism caused by chronic thyroiditis.

Claims (1)

黄連解毒湯及び苓桂朮甘湯の合剤を有効成分として含む慢性甲状腺炎による甲状腺機能低下症のホルモン異常を正常化させる漢方薬。 A herbal medicine that normalizes hormonal abnormalities in hypothyroidism caused by chronic thyroiditis, which contains a combination of Huangren detoxin and keikeienkanto.
JP2017081441A 2017-04-17 2017-04-17 Chinese medicine to normalize hormonal abnormalities of hypothyroidism due to chronic thyroiditis Active JP6154566B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017081441A JP6154566B1 (en) 2017-04-17 2017-04-17 Chinese medicine to normalize hormonal abnormalities of hypothyroidism due to chronic thyroiditis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017081441A JP6154566B1 (en) 2017-04-17 2017-04-17 Chinese medicine to normalize hormonal abnormalities of hypothyroidism due to chronic thyroiditis

Publications (2)

Publication Number Publication Date
JP6154566B1 true JP6154566B1 (en) 2017-06-28
JP2018177720A JP2018177720A (en) 2018-11-15

Family

ID=59218523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017081441A Active JP6154566B1 (en) 2017-04-17 2017-04-17 Chinese medicine to normalize hormonal abnormalities of hypothyroidism due to chronic thyroiditis

Country Status (1)

Country Link
JP (1) JP6154566B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6401414B1 (en) * 2018-03-30 2018-10-10 義輝 霜出 A Chinese medicine that improves cognitive function of Alzheimer-type dementia or mild cognitive impairment and treats at least one disease of the group consisting of overactive bladder and constipation associated therewith with a single agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102038917A (en) * 2009-10-15 2011-05-04 徐连群 Medicine for treating thyroid hypofunction
WO2013125225A1 (en) * 2012-02-23 2013-08-29 Shimoide Yoshiteru Composition for preventing or treating allergic disease or major depressive disorder (depression)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102038917A (en) * 2009-10-15 2011-05-04 徐连群 Medicine for treating thyroid hypofunction
WO2013125225A1 (en) * 2012-02-23 2013-08-29 Shimoide Yoshiteru Composition for preventing or treating allergic disease or major depressive disorder (depression)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6401414B1 (en) * 2018-03-30 2018-10-10 義輝 霜出 A Chinese medicine that improves cognitive function of Alzheimer-type dementia or mild cognitive impairment and treats at least one disease of the group consisting of overactive bladder and constipation associated therewith with a single agent
CN109568429A (en) * 2018-03-30 2019-04-05 霜出义辉 Improve the cognitive functions such as alzheimer dementia disease and passes through the Chinese medicine of its complication of single-dose treatment
US10660929B2 (en) 2018-03-30 2020-05-26 Yoshiteru Shimoide Kampo medicine for improving cognitive function in alzheimer-type dementia or mild cognitive impairment and treating at least one disease from the group consisting of overactive bladder, constipation, and chronic kidney diseases complicated by them with one drug
US11110142B2 (en) 2018-03-30 2021-09-07 Yoshiteru Shimoide Kampo medicine for improving cognitive function in Alzheimer-type dementia or mild cognitive impairment and treating at least one disease from the group consisting of overactive bladder, constipation, and chronic kidney diseases complicated by them with one drug

Also Published As

Publication number Publication date
JP2018177720A (en) 2018-11-15

Similar Documents

Publication Publication Date Title
CN1964730A (en) Herbal compositions for prevention and treatment rheumatic and inflammatory diseases and method of preparing the same
KR100980819B1 (en) The composition comprising complex herbal extract as an active ingredient and the preparation method thereof
HU187921B (en) Process for preparing an anticarcinogan pharmaceutical composition
CA2574721C (en) Ngna compositions and methods of use
CN101607074A (en) A kind of drug regimen for the treatment of chronic gastritis and preparation method thereof
JP6154566B1 (en) Chinese medicine to normalize hormonal abnormalities of hypothyroidism due to chronic thyroiditis
CN106334060A (en) Pharmaceutical composition for treating endomorphy type polycystic ovarian syndrome
CN116370556B (en) Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, tonifying qi and soothing nerves and preparation method thereof
WO2017124826A1 (en) Traditional chinese medicinal product for treating liver qi stagnation type premenstrual tension and syndrome
CN100444873C (en) Chinese medicinal formulation for treating spermophlebectasia
KR101864719B1 (en) Composition for prevention and treatment of osteoporosis comprising the extract of medicinal herb mixture
WO2016197878A1 (en) Pharmaceutical composition for treatment of menopausal syndrome and preparation method thereof
CN102552828B (en) Liver protecting medicine and preparation method thereof
JP2015508052A (en) Composition for prevention or treatment of allergic disease or major depressive disorder (depression)
KR20140043176A (en) Pharmacological composition for prevention and treatment of liver injury, and functional food including thereof
JPH0733676A (en) Composition for lowering blood suger value
Nesari et al. Fenugreek (Methika): Traditional Wisdom and Research Evidences
KR102070796B1 (en) Composition for preventing, alleviating or treating ovarian dysfunction comprising extract of medicinal herb mixture as effective component
CN114259540B (en) Traditional Chinese medicine composition for treating diabetes with syndrome of deficiency of both qi and yin and preparation method and application thereof
US20230405071A1 (en) Compositions and methods useful for management of blood sugar
KR102217732B1 (en) Composition for preventing and improving the development of premature pseudo-breast
NISTOR et al. POTENTIAL OF HERBS AS GALACTOGOGUES-A REVIEW.
CN108210873B (en) Traditional Chinese medicine composition for increasing estrogen and application thereof
CN101816708A (en) Treat rheumatismal Chinese medicine composition and preparation method thereof
KR20210157521A (en) Composition for preventing or treating type 2 diabetes mellitus comprising bo extract as effective component

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170417

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20170417

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20170508

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170601

R150 Certificate of patent or registration of utility model

Ref document number: 6154566

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250